ZIM Laboratories Sets Q2 FY27 Results Review for November 4

ZIM Laboratories Limited will consider its standalone and consolidated unaudited results for the quarter ended September 30, 2026, on November 4, following Q1 FY27 revenue of ₹94.18 crore and a consolidated net loss of ₹4.02 crore. The scheduled results and the following investor call will provide the next official update on operating performance and margins.

When will ZIM Laboratories announce its Q2 FY27 results?

ZIM Laboratories will hold a Board of Directors meeting on November 4, 2026, to consider and approve the unaudited standalone and consolidated financial results for Q2 FY27. The reporting quarter ended on September 30, 2026. The company disclosed the meeting schedule through a board-meeting intimation, with the trading window closed until November 6.

The announcement is significant because the company is due to report its first quarterly financial update after the June-quarter loss. Investors will look for the reported revenue, operating profit, margins and net profit or loss for the September quarter once the board approves the results. No Q2 FY27 financial figures were included in the company’s scheduling disclosures.

ZIM Laboratories has also scheduled an earnings conference call for November 5, 2026, at 11:00 a.m. IST. The call is being hosted by Go India Advisors and is intended to cover the company’s Q2 and first-half FY27 operating and financial performance.

The management team listed for the call includes Chairman and Managing Director Dr. Anwar Siraj Daud, Director - Finance Zulfiquar Kamal, Chief Financial Officer Shyam Mohan Patro and investor relations representative Zain Daud. Investors can register for the call through DiamondPass, according to the company’s announcement.

What did ZIM Laboratories report in Q1 FY27?

ZIM Laboratories reported consolidated revenue from operations of ₹94.18 crore for the quarter ended June 30, 2026, up 31.2% year on year from ₹71.76 crore. However, sales declined 10.5% sequentially from the March 2026 quarter, when revenue was about ₹105 crore.

The company recorded a consolidated net loss of ₹4.02 crore in Q1 FY27, compared with a net loss of ₹1.87 crore in Q1 FY26 and a net profit of ₹3.74 crore in Q4 FY26. Basic earnings per share stood at a loss of ₹0.75, compared with a loss of ₹0.38 in the corresponding prior-year quarter.

Operating profitability weakened during the June quarter. Operating profit was ₹2.45 crore, against ₹4.25 crore a year earlier, while the operating profit margin declined to 2.60% from 5.92%. Reported EBITDA was ₹2.45 crore and the EBITDA margin was 2.6%, with higher expenses affecting profitability.

Why are margins and export markets relevant to the Q2 update?

Margins and export-market progress are relevant because ZIM Laboratories drew about 84% of its June-quarter revenue from exports. Pharmaceuticals accounted for about 72% of revenue, while nutraceuticals contributed about 28%. The company also identified innovative and thin-film products as accounting for about 18% of revenue.

The June-quarter revenue gain did not translate into profit because total expenses rose 33.1% year on year to ₹100.74 crore. Loss before tax was ₹5.57 crore. This contrast between sales growth and cost growth makes the next margin update important for investors assessing the company’s operating performance.

ZIM Laboratories has stated that regaining EU-GMP accreditation is a priority in FY27. The company described the final EU-GMP inspection report as important for access to regulated European markets and had indicated an expectation to begin EU supplies by Q4 FY27. The September-quarter results and call may offer an official update on this disclosed process, if management addresses it.

The company’s quarterly operating margin has varied materially in recent periods. It was 13.43% in March 2025, 11.79% in December 2025, 6.83% in March 2026 and 2.60% in June 2026. This pattern places attention on whether costs, product mix and export activity changed during Q2 FY27.

How could the scheduled disclosures affect investors and operations?

The November 4 results will give investors the company’s first official financial comparison for the first half of FY27, while the November 5 call creates a forum for management to explain the reported performance. Until the board-approved filing is released, revenue, profitability and margin outcomes for Q2 FY27 remain undisclosed.

For shareholders, the relevant reported benchmarks include Q1 revenue of ₹94.18 crore, operating margin of 2.60% and the ₹4.02 crore net loss. The September-quarter results can show whether the June-quarter revenue growth continued and whether the higher expense base remained a constraint. These are matters for the financial filing rather than conclusions that can be drawn from the meeting notice.

For company operations, the disclosed EU-GMP remediation and planned European supplies remain important because exports form the majority of revenue. The company has not provided a fresh approval status in the meeting and conference-call notices. Any update on the final inspection report or the timing of EU supplies would need to come from management or a subsequent regulatory filing.

The scheduled conference call also gives market participants an opportunity to hear management’s comments directly after the results. The company has named the participating executives, but the notice does not set financial targets for Q2 FY27 or for the full year.

Conclusion

ZIM Laboratories is scheduled to place its Q2 FY27 standalone and consolidated results before the board on November 4, followed by an investor call on November 5. The update follows a June quarter in which revenue rose 31.2% year on year to ₹94.18 crore, but operating margin fell to 2.60% and the company posted a ₹4.02 crore consolidated loss.

The immediate item to watch is the board-approved September-quarter filing, including revenue, expenses, operating margin and net profit or loss. Investors will also watch for any management update on the final EU-GMP inspection report and the company’s previously indicated plan to start EU supplies by Q4 FY27.